Helen Hahn is a seasoned leader in the field of medical affairs, currently serving as the Director of Medical Affairs for Regenerative Medicine at Mallinckrodt Pharmaceuticals. In this pivotal role, she is at the forefront of developing and executing the medical strategy for the launch...
Helen Hahn is a seasoned leader in the field of medical affairs, currently serving as the Director of Medical Affairs for Regenerative Medicine at Mallinckrodt Pharmaceuticals. In this pivotal role, she is at the forefront of developing and executing the medical strategy for the launch of a groundbreaking biologics license application (BLA) product, specifically an allogeneic cellular tissue product. Helen's extensive experience in medical strategy and product launches positions her as a key driver in ensuring the successful introduction of innovative therapies that have the potential to transform patient care.
Her responsibilities encompass a broad spectrum of medical affairs deliverables, where she provides scientific and strategic vision that underpins critical initiatives. This includes the formulation of a robust publication strategy that disseminates key findings and insights to the medical community, as well as the development of comprehensive medical education programs designed to equip healthcare professionals with the knowledge necessary to utilize these advanced therapies effectively. Helen excels in cross-functional team leadership, collaborating seamlessly with clinical development, regulatory affairs, and commercial teams to align objectives and mitigate risks throughout the product lifecycle.
In addition to her strategic acumen, Helen is passionate about mentoring and coaching emerging leaders in the medical affairs space, fostering a culture of thought leadership and innovation. Her ability to navigate complex regulatory landscapes while maintaining a focus on business strategy and compliance underscores her commitment to excellence in the pharmaceutical industry. With a keen eye for strategic planning and a deep understanding of clinical research, Helen Hahn is poised to make a significant impact in the regenerative medicine arena, driving forward the mission of Mallinckrodt Pharmaceuticals to deliver life-changing therapies to patients in need.
